To find the recommended dose of the combination of avutometinib, defactinib, and everolimus in patients with endometrial cancer that is recurrent and has abnormal RAS activity. The safety and effects of this combination will also be studied.

开始日期2026-06-03

申办/合作机构

The University of Texas MD Anderson Cancer Center

[+1]

NCT07126158

/ Not yet recruiting临床2期IIT

Phase II Study of Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma

Advanced pancreatic cancer patients receiving treatment of adaptive stereotactic body radiotherapy (SBRT) with concurrent and adjuvant defactinib plus avutometinib will have increased progression-free survival (PFS) compared to historical PFS rates for patients receiving adaptive SBRT alone.

开始日期2026-04-30

申办/合作机构

Washington University School of Medicine

[+2]

NCT06104488

/ Recruiting临床1期IIT

\Multi-Center Phase I Study of Avutometinib (VS-6766), a RAF/MEK Clamp in Combination With Defactinib, a FAK Inhibitor, in Pediatric Patients With Refractory or Recurrent Solid Tumors Harboring Activating MAPK Pathway or NF2 Alterations

The purpose of this study is to find out whether avutometinib is a safe treatment for advanced or recurrent solid tumor cancers in children and young adults. Researchers will look for the highest dose of avutometinib that is safe and cause few or mild side effects.

开始日期2023-10-20

申办/合作机构

Memorial Sloan Kettering Cancer Center

100 项与 Avutometinib 相关的临床结果

登录后查看更多信息

100 项与 Avutometinib 相关的转化医学

登录后查看更多信息

100 项与 Avutometinib 相关的专利（医药）

登录后查看更多信息

项与 Avutometinib 相关的文献（医药）

2026-03-01·Trends in Cancer

Disarming cancer resistance: FAK as a therapeutic target

Review

作者: Schlaepfer, David D ; Haanen, Terrance J

The FDA recently granted accelerated approval of the small-molecule focal adhesion kinase (FAK) inhibitor (FAKi, defactinib) in combination with a RAF-MEK clamp inhibitor (avutometinib) for KRAS-mutated low-grade serous ovarian cancer developed by Verastem Inc. This milestone moment represents a long journey in FAKi development, from initial findings of limited single-agent activity to orally delivered FAKi effects that can sensitize solid tumors to chemotherapy, radiotherapy, and immunotherapy treatments. In this study, we review a short history of FAK, summarize ongoing combinatorial clinical trials, discuss potential mechanisms of action, and highlight studies showing that FAK activation is a chemo- and mechano-sensitive signaling hub driving tumor adaptive changes. Targeting FAK disarms tumor resistance through multiple mechanisms, which supports new biological insights and future clinical combinations.

2026-02-01·Gynecologic Oncology Reports

Long lasting response to the combination of Avutometinib and Defactinib after progression on Binimetinib in a patient with recurrent low grade serous ovarian carcinoma − A case report

Article

作者: Palmieri, Luca ; Greenman, Michelle ; Santin, Alessandro D ; Ettorre, Victoria M ; Ottum, Sarah

Background:

Treatment of recurrent chemotherapy, aromatase (AI) and MEK Inhibitor (MEKi) resistant low grade serous ovarian cancer (LGSOC) remains a challenge. Novel treatment options for KRAS mutated MEKi resistant LGSOC are warranted.

Case:

A 73-year-old with recurrent, metastatic, platinum-resistant LGSOC harboring a KRAS mutation experienced a prolonged response to the combination of Avutometinib and Defactinib after failing multiple lines of chemotherapy, aromatase inhibitor (AI), and targeted therapy with the MEK inhibitor Binimetinib (MEK-162). Following Avutometinib and Defactinib treatment, she experienced a confirmed and long-lasting (4 years) partial response as well as a return of CA-125 to baseline. The oral drug combination was well tolerated with no dose-limiting toxicity or need for dose reduction over the 4 year period.

Conclusion:

The Avutometinib and Defactinib combination may represent a new standard treatment option for platinum-resistant and AI-resistant/recurrent LGSOC who have failed other MEKi.

2026-01-01·GYNECOLOGIC ONCOLOGY

Co-targeting the PI3K-Akt pathway improves response to MEK inhibition in low-grade serous ovarian cancer cell lines

Article

作者: Goodheart, Michael J ; Dupuy, Adam J ; Peplinski, Rebekah M ; Schillo, Jacob L ; Ulmer, Keely K ; Lyons, Yasmin A ; Hannan, Elizabeth C ; Nobre, Silvana Pedra ; Riordan, Jesse D

OBJECTIVE:

Low-grade serous ovarian cancer (LGSOC) frequently harbors genetic alterations that activate the MAPK pathway, providing an oncogenic target for therapeutic intervention. Recent clinical trials utilizing inhibitors of MEK (a key mediator of MAPK signaling), particularly trametinib or avutometinib/defactinib combination, have shown efficacy in patients with recurrent LGSOC. Unfortunately, however, nearly all patients eventually develop therapeutic resistance and progressive disease, which confers a dismal prognosis. Here, we aim to characterize biological responses of LGSOC to MEK inhibition at the molecular level.

METHODS:

We performed a kinome-focused CRISPR knockout screen in LGSOC cell lines to identify synthetic lethal interactions between trametinib treatment and loss of specific protein kinases. Candidates were evaluated using western blotting and cell viability assays.

RESULTS:

CRISPR kinome screens identified several protein kinases, particularly within the PI3K-Akt pathway, whose loss correlated with outgrowth of trametinib-resistant LGSOC cell populations, indicative of synthetic lethal interaction. Western blotting confirmed upregulation of Akt signaling upon MEK inhibition in a panel of LGSOC cell lines, and preventing this upregulation by co-inhibiting AKT with capivasertib produced synergistic antiproliferative effects in vitro.

CONCLUSION:

LGSOC responds to MEK inhibition by upregulating PI3K-Akt signaling, thereby promoting cell survival and proliferation. Our research identified significant upregulation of the PI3K-Akt pathway in response to MEK inhibition. While targeted inhibition of AKT had minimal impact alone, combination with MEK inhibitors produced strong synergistic suppression of proliferation in LGSOC cells. This combination strategy could potentially be used to prevent or reverse the emergence of MEK inhibitor resistance in LGSOC patients.

186

项与 Avutometinib 相关的新闻（医药）

2026-04-01

·ioncology

2026 SGO全体大会精粹：妇科肿瘤关键临床试验与治疗策略更新

2026年美国妇科肿瘤学会（SGO）年会将于4月10-13日在波多黎各圣胡安举行。作为全球妇科肿瘤领域的顶级学术盛会，本届年会在Exhibit Hall A举办五场全体大会（Scientific Plenary），集中展示了从靶向治疗、免疫疗法到手术革新和遗传学管理的最新进展。以下是各场全体大会的核心内容介绍。全体大会 I：Advancing Science through Clinical Trials（通过临床试验推进科学）时间：2026年4月10日（周五）4:45 PM - 5:45 PM AST 主持专家：Pamela Soliman, MD；Christine Walsh, MD 英文标题：Final Overall Survival (OS) Results From the Phase 3 ROSELLA Trial: Relacorilant Plus Nab-Paclitaxel vs Nab-Paclitaxel Monotherapy in Patients With Platinum-Resistant Ovarian Cancer (PROC) (GOG-3073, ENGOT-ov72, APGOT-Ov10, and LACOG-0223) 中文标题：III期ROSELLA试验的最终总生存期结果：Relacorilant联合白蛋白紫杉醇对比白蛋白紫杉醇单药治疗铂耐药卵巢癌患者（GOG-3073、ENGOT-ov72、APGOT-Ov10、LACOG-0223）讲者：Alexander Olawaiye, MD 英文标题：Encore: Pembrolizumab vs Placebo Plus Weekly Paclitaxel ± Bevacizumab in Platinum-Resistant Recurrent Ovarian Cancer: Final Analysis Results from the Randomized Double-Blind Phase 3 ENGOT-ov65/KEYNOTE-B96 Study 中文标题：再现：帕博利珠单抗对比安慰剂联合周疗紫杉醇±贝伐珠单抗治疗铂耐药复发性卵巢癌——随机双盲III期ENGOT-ov65/KEYNOTE-B96研究最终分析结果讲者：Bradley Monk, MD 英文标题：Long-Term Efficacy and Safety of Avutometinib + Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer: Results from ENGOT-OV60/GOG-3052/RAMP 201 中文标题：Avutometinib+Defactinib治疗复发性低级别浆液性卵巢癌的长期疗效与安全性：ENGOT-OV60/GOG-3052/RAMP 201研究结果讲者：Rachel Grisham, MD 英文标题：GOG-3039: A Phase II Trial of Abemaciclib Plus Letrozole in Recurrent or Persistent Endometrioid Endometrial Carcinoma (NCT04393285) 中文标题：GOG-3039：阿贝西利联合来曲唑治疗复发或持续性子宫内膜样子宫内膜癌的II期试验（NCT04393285）讲者：Marilyn Huang, MD, MS, FACOG 英文标题：Results of a Randomized Phase III Trial of Letrozole Alone Versus Paclitaxel and Carboplatin Followed by Letrozole as Initial Treatment for Patients with Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Low-Grade Serous Carcinoma (NRG-GY019, NCT04095364) 中文标题：来曲唑单药对比紫杉醇+卡铂序贯来曲唑作为II-IV期卵巢、输卵管或原发性腹膜低级别浆液性癌初始治疗的随机III期试验结果（NRG-GY019，NCT04095364）讲者：Amanda Fader, MD 总结与点评（Distillation）点评专家：Roisin O'Cearbhaill, MD 全体大会 II：Transforming Endometrial Cancer Care（变革子宫内膜癌治疗）时间：2026年4月11日（周六）8:45 AM - 9:30 AM AST 主持专家：Eloise Chapman-Davis, MD；Rebecca Arend, MD, MPH 英文标题：Trastuzumab Pamirtecan (DB-1303/BNT323) in patients with previously treated HER2-expressing advanced/metastatic endometrial cancer: First global clinical Phase 2 data 中文标题：DB-1303用于经治的HER2表达晚期/转移性子宫内膜癌患者：首次全球临床II期数据讲者：Bhavana Pothuri, MD, MS 英文标题：Efficacy and safety of cadonilimab combined with chemotherapy as the first-line treatment for recurrent/advanced endometrial carcinoma: a multi-center, single-arm phase II clinical trial 中文标题：卡度尼利单抗联合化疗一线治疗复发/晚期子宫内膜癌的疗效与安全性：一项多中心、单臂II期临床试验讲者：Yang Sun, MD 英文标题：The social interventions for support in treatment of endometrial cancer and recurrence (SISTER) study: A national randomized controlled trial of peer support vs. usual care in Black women with high-risk endometrial cancer 中文标题：子宫内膜癌及复发治疗中的社会支持干预（SISTER）研究：一项针对高危子宫内膜癌黑人女性的全国性同伴支持对比常规护理的随机对照试验讲者：Kemi Doll, MD, MSCR 英文标题：Facilitated Genetic Cascade Testing (FaCT): A Prospective Multi-Institutional Randomized Controlled Trial 中文标题：促进式遗传级联检测（FaCT）：一项前瞻性多机构随机对照试验讲者：Roni Nitecki Wilke, MD, MPH 总结与点评（Distillation）点评专家：Bradley Corr, MD 全体大会 III：Surgical Showdown - Farr Nezhat Session（外科对决——Farr Nezhat专场）时间：2026年4月11日（周六）11:35 AM - 12:35 PM AST 主持专家：Nicole Fleming, MD；John Moroney, MD 英文标题：Introduction and Announcement of Surgical Film Winner 中文标题：专场介绍，外科手术影片获奖者公布讲者：Farr Nezhat, MD, FACOG, FACS 英文标题：Renal Vein Angle and Standardized Technique for Single-Port Laparoscopic Paraaortic Lymphadenectomy 中文标题：基于肾静脉角度的单孔腹腔镜腹主动脉旁淋巴结清扫标准化技术讲者：Hua Tu, MD 英文标题：Laparoscopic Uterine & Ovarian Transposition with Oophoropexy and Cervical Stoma Creation 中文标题：腹腔镜子宫卵巢移位、固定及宫颈造口术讲者：Robert DeBernardo, MD 总结与点评（Distillation）点评专家：Emma Rossi, MD 英文标题：Debate - Primary Cytoreductive Surgery (PCS) 中文标题：辩论——初次肿瘤细胞减灭术讲者：Carrie Langstraat, MD 英文标题：Debate - Neoadjuvant Chemotherapy (NACT) 中文标题：辩论——新辅助化疗讲者：Jason Wright, MD 全体大会 IV：Innovate to Eliminate - New Therapeutics（创新以消除妇瘤——新疗法）时间：2026年4月12日（周日）10:00 AM - 11:00 AM AST 主持专家：Edwin Alvarez, MD；John Hays, MD, PhD 英文标题：Mocertatug rezetecan (GSK5733584), a B7-H4-targeted antibody-drug conjugate (ADC), in platinum-resistant ovarian cancer (PROC) and endometrial cancer (EC): First results from the global BEHOLD-1 study 中文标题：Mocertatug rezetecan（GSK5733584），一种靶向B7-H4的抗体药物偶联物，治疗铂耐药卵巢癌和子宫内膜癌：全球BEHOLD-1研究的首次结果讲者：Ana Oaknin, MD, PhD 英文标题：SYS6043, a B7-H3 targeting antibody-drug conjugates in patients with advanced gynecologic cancers: a phase 1/2, first-in-human study 中文标题：靶向B7-H3的抗体药物偶联物SYS6043用于晚期妇科癌症患者：一项I/II期首次人体研究讲者：Jing Zuo, MD 英文标题：Updated results from the first-in-human phase 1 study of LY4170156, an antibody drug conjugate (ADC) targeting folate receptor alpha (FRα) in recurrent platinum resistant high-grade serous ovarian cancer (HGSOC) 中文标题：靶向叶酸受体α的抗体药物偶联物LY4170156治疗复发铂耐药高级别浆液性卵巢癌的首次人体1期研究更新结果讲者：Bhavana Pothuri, MD, MS 英文标题：The pivotal PYNNACLE Phase 2 trial assessing rezatapopt, a selective p53 reactivator, in patients with advanced or metastatic solid tumors harboring a TP53 Y220C mutation: Interim analysis of patients with ovarian cancer 中文标题：评估选择性p53再激活剂rezatapopt治疗携带TP53 Y220C突变的晚期或转移性实体瘤患者的关键性PYNNACLE II期试验：卵巢癌患者的中期分析讲者：Alison Schram, MD 英文标题：Phase II Study of Camrelizumab plus Apatinib Combined with Chemotherapy in High-Risk, Chemoresistant Gestational Trophoblastic Neoplasia 中文标题：卡瑞利珠单抗联合阿帕替尼及化疗治疗高危、耐药性妊娠滋养细胞肿瘤的II期研究讲者：蒋芳教授总结与点评（Distillation）点评专家：Stephanie Gaillard, MD, PhD 全体大会 V：Emerging Strategies in Cervical Cancer Care（宫颈癌治疗的新兴策略）时间：2026年4月13日（周一）11:15 AM - 12:15 PM AST 主持专家：Charles Leath, III, MD, MSPH；Roberto Vargas, MD 英文标题：Sacituzumab Tirumotecan (Sac-TMT) Plus Pembrolizumab in Participants With Recurrent or Metastatic Cervical Cancer: Results From the Phase 2 2870-002/SKB264-II-06 Study 中文标题：Sac-TMT联合帕博利珠单抗治疗复发或转移性宫颈癌：II期2870-002/SKB264-II-06研究结果讲者：吴小华教授英文标题：Tisotumab vedotin in combination with carboplatin and pembrolizumab with or without bevacizumab in first-line recurrent or metastatic cervical cancer: first disclosure of arm H from the ENGOT-cx8/GOG-3024/innovaTV 205 study 中文标题：Tisotumab vedotin联合卡铂和帕博利珠单抗±贝伐珠单抗一线治疗复发或转移性宫颈癌：ENGOT-cx8/GOG-3024/innovaTV 205研究中H组的首次数据公布讲者：Toon Van Gorp, MD, PhD 英文标题：Development of ENG–Targeted CAR T cells for cervical cancer: Direct tumor targeting and microenvironment modulation 中文标题：靶向ENG的CAR-T细胞治疗宫颈癌的开发：直接靶向肿瘤与微环境调控讲者：Min Guan, MD, PhD 英文标题：Exclusion of Individuals with HIV from Cervical Cancer Clinical Trials: Lack of Progress in the Immunotherapy Era 中文标题：宫颈癌临床试验中HIV感染者的排除问题：免疫治疗时代进展寥寥讲者：Lauren Gottshall, MD 总结与点评（Distillation）点评专家：Ritu Salani, MD, MBA （来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

临床3期免疫疗法临床2期临床结果

2026-03-25

·氟档案

【经典综述】2025年美国FDA批准的含氟药物_2026_P14（预印本）

导言本综述重点介绍了美国食品药品监督管理局 (FDA) 于 2025 年批准的 14 种新药，包括 datopotamab deruxtecan、suzetrigine、mirdametinib、avutometinib/defactinib、taletrectinib、sunvozertinib、sebetralstat、rilzabrutinib、imlunestrant、paltusotine、remibrutinib、elinzanetant、ziftomenib 和 zoliflodacin。对于每种化合物，我们考察了其药物化学发现、治疗应用和 FDA 批准时间线，尤其侧重于合成策略和氟引入的作用。本综述旨在为学术界和制药行业的科研人员以及从事药物设计、氟化学和药物化学的学生提供及时的参考和启发。 ➤ 欢迎来到氟叫兽的氟档案馆，微信：dowpont。免费下载，转发本号任一文章后加氟叫兽微信dowpont获取下载密码： Fluorine-containing drugs approved by the US FDA in 2025.pdf 概述含氟药物设计已成为现代药物研发的核心策略之一。氟原子凭借其极高的电负性（鲍林标度3.98）和与氢原子相近的范德华半径（约1.47 Å），在引入药物分子后能够显著改善脂溶性、代谢稳定性、靶点结合亲和力及pKa值，从而全面提升药物的疗效、生物利用度和药代动力学性质。因此，氟原子常被药物化学家誉为"魔法原子"——即便是单个氟原子的引入，也可能彻底改变一个候选药物的命运。本文系统梳理了2025年美国FDA批准上市的14款含氟新药，涵盖其药物化学发现历程、治疗适应症、审批时间线，并重点阐述合成策略与氟原子引入的作用机制。 14款含氟新药概览 1. 达妥珠单抗德鲁替康（Datroway）这是一款靶向TROP2的抗体药物偶联物，于2025年1月获批用于HR+/HER2-不可切除或转移性乳腺癌。其含氟组分为依沙替康，属于喜树碱拓扑异构酶I抑制剂类似物，A环的氟化修饰显著增强了体内外细胞毒性并降低了系统毒性。 2. 苏泽曲金（Journavx）2025年1月获批，是首个获批用于中重度急性疼痛的NaV1.8电压门控钠通道选择性抑制剂，属于非阿片类镇痛药。其结构含三氟甲基和3,4-二氟-2-甲氧基苯基，氟取代基赋予分子对靶点疏水空腔的强结合力，并提升代谢稳定性。 3. 米达美替尼（Gomekli）2025年2月获批，用于2岁及以上有症状性丛状神经纤维瘤的1型神经纤维瘤病患者。作为MEK1/2抑制剂，其二苯胺骨架上的多个氟取代基通过与MEK1结合口袋中Lys97和Ser212形成特异性相互作用，显著提升抑制活性。 4. 阿伏美替尼/德法替尼（Avmapki）2025年5月获批，用于KRAS突变的复发性低级别浆液性卵巢癌。两药联合分别靶向Raf/MEK（阿伏美替尼，吡啶上的氟提升代谢稳定性）和FAK（德法替尼，CF₃基团通过卤键与FAK疏水位点Asp564相互作用）。 5. 他来替尼（Ibtrozi）2025年6月获批，用于ROS1阳性晚期非小细胞肺癌（NSCLC）。SAR研究表明苯环上的氟原子对ROS1激酶抑制活性至关重要，含氟化合物的IC₅₀值（<20 nmol/L）远优于无氟对照物。 6. 孙伏泽替尼（Zegfrovy）2025年7月加速获批，用于EGFR外显子20插入突变的晚期NSCLC。4-氟和5-氯的联合取代将人肝细胞清除率从34 μL/min/10⁶细胞显著降低至7.1 μL/min/10⁶细胞，大幅改善药代动力学特性。 7. 塞贝曲司他（Ekterly）2025年7月获批，用于遗传性血管性水肿的急性发作治疗，通过抑制血浆激肽释放酶阻断缓激肽过度生成。氟原子通过gauche效应调节分子构象，优化亲脂性、膜渗透性和清除率。 8. 利扎布鲁替尼（Wayrilz）2025年8月获批，为可逆性BTK抑制剂，用于对其他疗法无效的慢性免疫性血小板减少症。单个氟原子的引入使BTK抑制活性IC₅₀达1.3 nmol/L，在全血CD69 B细胞激活试验中表现出高效抑制活性。 9. 伊姆奈司坦（Inluriyo）2025年9月获批，为脑渗透性选择性雌激素受体降解剂，用于ESR1突变的ER+/HER2-晚期乳腺癌。CF₃基团的引入使其与ERα的结合亲和力（Ki = 0.64 nmol/L）较非三氟甲基化类似物提高了约12～42倍。 10. 帕图索汀（Palsonify）2025年9月获批，为首个非肽类SST2受体激动剂，用于手术后控制不佳的肢端肥大症。3,5-二氟苯基取代赋予其对hSST2的超高效力（EC₅₀ = 0.25 nmol/L），并实现对其他SST亚型超过1000倍的选择性。 11. 雷米布鲁替尼（Rhapsido）2025年9月获批，为高选择性共价BTK抑制剂，用于慢性自发性荨麻疹。氟化修饰使其BTK抑制活性提升约3倍（IC₅₀从3.8降至1.3 nmol/L），同时改善膜渗透性。 12. 依林扎奈坦（Lynkuet）2025年10月获批，为NK1/NK3双受体拮抗剂，用于更年期中重度血管舒缩症状。CF₃基团的引入将受体结合亲和力较类似物提高约5～50倍，且无激素类副作用。 13. 齐夫托美尼（Komzifti）2025年11月获批，为选择性menin抑制剂，用于NPM1突变的复发难治性急性髓系白血病。含氟噻吩并嘧啶核心结构实现IC₅₀ < 50 nmol/L的高效抑制，代表精准表观遗传靶向治疗的重大突破。 14. 佐利弗洛达星（Nuzolvence）2025年12月获批，为首创口服螺嘧啶三酮类抗生素，用于淋球菌性泌尿生殖道感染，对多药耐药菌株有效，且与氟喹诺酮类无交叉耐药性。总结与展望 14款新药涵盖肿瘤、疼痛、免疫、内分泌及感染性疾病等广泛治疗领域，均含杂环骨架，多数为手性化合物。从氟化模式来看，芳香单氟取代最为常见（10/14），其次为CF₃取代和二氟取代，脂肪族氟化最少。这些规律与历年趋势高度一致，反映了氟原子在微调电子密度、提升代谢稳定性和阻断代谢热点方面的不可替代性。未来的挑战在于开发更绿色高效的氟化合成方法、探索新型氟化模式，并借助人工智能辅助预测氟化位点，同时也需关注含氟药物在环境中的持久性与降解问题。精彩回顾：氟叫兽写的创刊号文章【创刊号系列之三】氟叫兽重写氟的发现历史-3：氟化学的祖师爷_亨利·莫瓦桑(Henri Moissan)—（完）【创刊号系列之三】氟叫兽重写氟的发现历史-2：氟的发现史（莫瓦桑前的悲壮过程）【创刊号系列之三】氟叫兽重写氟的发现历史-1：再识萤石【创刊号系列之二】氟叫兽重写氟的发现历史-2：中日近代氟元素名称起源对比（民国前）【创刊号系列之二】氟叫兽重写氟的发现历史-2：中国近代氟化学知识起源考（民国前）【创刊号系列之二】氟叫兽重写氟的发现历史-2：日本萤石名称考【创刊号系列之二】氟叫兽重写氟的发现历史-1：中国古代萤石名称考（上一篇的补充）【创刊号系列之二】氟叫兽重写氟的发现历史-1：中国古代萤石名称考【创刊号系列之一】氟叫兽带你重新认识“氟” 氟叫兽建的氟档案馆 PTFE PVDF FEP ETFE FKM 氟精细无机氟氟气体氟流体报告手册书籍剪报数据人物综合其它免责声明：本公众号部分文字及图片来源于网络，仅供学习、交流使用，版权归原作者所有，如有问题请及时联系处理，氟叫兽微信：dowpont。本号文章并不代表氟叫兽本人意见，欢迎转发，请注明出处。上面内容直接点进入合集。

2026-03-20

·BioSpace

Kaida BioPharma Announces Executive Leadership Team to Advance KAD-101, Built for the Ovarian Cancer Gap

FORT LAUDERDALE, Fla., March 19, 2026 (GLOBE NEWSWIRE) -- Kaida BioPharma, a biotechnology company developing targeted therapies for women with hard-to-treat gynecologic cancers, today announced its executive leadership team and board. Each member brings decades of experience in biotechnology, clinical development, regulatory strategy, manufacturing, finance, and commercialization to help advance Kaida’s lead product candidate, KAD-101, toward first-in-human clinical evaluation. The company is developing KAD-101 for recurrent ovarian cancer, where treatment options narrow quickly and durable control remains limited. Kaida BioPharma is building KAD-101, a next-generation prolactin receptor antagonist for the ovarian cancer gap, the space where patients are too often left cycling through treatment with too few durable options. In addition to her role as Chairperson of the Board, Kaida founder Dr. Stella Vnook has been named Acting Chief Executive Officer. Dr. Vnook is an accomplished biotechnology founder, executive, and advisor with extensive experience guiding early-stage therapeutics from scientific foundation through capital formation. At Kaida, she leads corporate strategy, development planning, and investor engagement. “The science brought me here, and the women out there still fighting are why I stay. At Kaida, we are building for the ovarian cancer gap, for patients whose options narrow too fast and whose disease still outpaces available therapies,” said Dr. Vnook. “By targeting the survival signals that keep these tumors alive, we believe KAD-101 has the potential to help overcome treatment resistance and create a new path toward more durable control. More options mean more time, and more time means everything.” Craig Pierson , a founder alongside Dr. Vnook, has been appointed Director at Kaida BioPharma. Mr. Pierson is a life sciences investor and company builder with more than 25 years of experience in investment banking and private capital formation. He provides strategic oversight and financing expertise. George E. Peoples, MD, FACS has been appointed fractional Chief Medical Officer. Dr. Peoples is a surgical oncologist with decades of experience in translational oncology and clinical development. He is also the founder of the Cancer Vaccine Development Program, Cancer Insight, and LumaBridge. At Kaida, he helps guide clinical strategy and IND planning. John Langenheim, PhD has been appointed fractional Chief Scientific Officer. Dr. Langenheim is a molecular biologist with more than 20 years of experience in therapeutic protein design and preclinical development. His scientific leadership has been instrumental in advancing KAD-101 toward clinical evaluation. Pamela Swiggard has been appointed Head of Regulatory Affairs. She is a pharmaceutical executive with prior experience at companies including Pfizer and Endo Pharmaceuticals. She brings deep expertise across the product lifecycle, from development through regulatory approval and commercialization. At Kaida, she leads regulatory strategy and FDA engagement in support of IND readiness for KAD-101. Eric Hacherl, PhD has been appointed Head of Manufacturing. Dr. Hacherl is a senior pharmaceutical operations leader with more than 25 years of experience in biologics manufacturing, cGMP compliance, and process development. At Kaida, he is responsible for helping ensure clinical supply readiness for KAD-101. Mark Booth has been appointed Chief Commercial Officer. Mr. Booth is a seasoned pharmaceutical and biotechnology executive with more than 25 years of experience building commercial strategies for oncology and rare disease products. His background includes leadership across launch planning, brand strategy, access, and market development for important oncology products, including EMEND, EMEND IV, Zolinza, vintafolide, KEYTRUDA, and the avutometinib plus defactinib combination for low grade serous ovarian cancer. At Kaida, he is responsible for commercial strategy for KAD-101, including positioning, market development, and long-term access planning. About Kaida BioPharma Kaida BioPharma is a biopharmaceutical company developing targeted therapies for hormone-driven gynecologic cancers. Its lead candidate, KAD-101, is a prolactin receptor antagonist being developed for recurrent ovarian cancer, where treatment options narrow quickly and many patients still face limited durable control. Kaida is focused on building innovative therapies for patients left in the ovarian cancer gap and in other areas of high unmet need. For more information, visit kaida-biopharma.com . Contact: Michelle Kafka michelle@kafka.com 407-603-5716

高管变更疫苗

100 项与 Avutometinib 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB15254

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
晚期胰腺腺癌	临床2期	美国	Verastem, Inc.	2026-04-30
胰腺腺癌	临床2期	美国	Verastem, Inc.	2026-04-30
HR阳性乳腺癌	临床2期	美国	Verastem, Inc.	2023-02-23
HR阳性/HER2阴性乳腺癌	临床2期	美国	Verastem, Inc.	2023-02-23
转移性胰腺腺癌	临床2期	美国	Verastem, Inc.	2023-01-15
大肠腺癌	临床2期	美国	Verastem, Inc.	2022-08-22
晚期结直肠腺癌	临床2期	美国	Verastem, Inc.	2022-08-22
KRAS 突变结直肠癌	临床2期	美国	Verastem, Inc.	2022-08-22
转移性结直肠癌	临床2期	美国	Verastem, Inc.	2022-08-22
晚期癌症	临床2期	美国	Verastem, Inc.	2022-08-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06072781 \| NCT04625270 (ENGOT-OV60/GOG-3052/RAMP 201, Pubmed \| J Clin Oncol)	临床2期	卵巢浆液性肿瘤	115	Avutometinib 4.0 mg monotherapy	構獵選顧淵範鏇蓋遞選(糧製網製膚構獵憲憲願) = 積積鬱壓艱壓壓製憲簾鬱糧製齋夢糧獵襯醖鹹 (繭鹹襯壓網積襯獵齋積, 23 ~ 41) 更多	积极	2025-09-01
NCT05669482 (RAMP 205, ASCO2025)	临床1/2期	转移性胰腺导管腺癌一线 activating KRAS mutations	54	Avutometinib/Defactinib + Gemcitabine/nab-paclitaxel	糧窪夢衊夢鏇獵餘齋繭(衊鹹膚製簾鬱選醖膚夢) = 41% 壓鹹醖襯網獵製選遞憲 (鑰夢網鏇鏇壓鑰獵觸積 ) 更多	积极	2025-05-30
NCT05669482 (RAMP205, Biospace) 人工标引	临床1/2期	转移性胰腺导管腺癌一线	60	avutometinib + defactinib + gemcitabine + Nab-paclitaxe (dose level 1 cohort)	製齋鏇淵齋繭繭選獵淵(築窪醖蓋鑰糧積選蓋艱) = 製夢憲願齋壓廠壓憲築齋鹽獵積衊蓋鹹鏇膚壓 (觸夢願鹽淵範膚醖選鹽 ) 更多	积极	2025-05-23
NCT05669482 (RAMP205, Biospace) 人工标引	临床1/2期	转移性胰腺导管腺癌一线	60	avutometinib + defactinib + gemcitabine + Nab-paclitaxe	膚餘簾鹽蓋遞網憲簾簾(選積範繭窪憲獵醖選鹽) = 選觸衊壓襯醖壓鑰襯壓齋夢壓廠鏇壓餘製構築 (遞獵糧遞淵衊製鏇願獵 )	积极	2025-05-23
phase 1 trial (AACR2025)	临床1期	转移性乳腺癌 CDK4/6 inhibitor (CDK4/6i)	16	Avutometinib 3.2 mg PO BIW	衊憲鹽鬱鹽網艱糧觸鹹(選遞壓觸夢衊選範廠鹽) = 構願蓋鹹積觸憲網齋範製網鹹遞壓廠遞範網醖 (蓋遞餘糧蓋獵醖繭艱蓋 ) 更多	积极	2025-04-28
NCT05074810 (RAMP 203, BusinessWire) 人工标引	临床1/2期	KRAS G12C突变非小细胞肺癌 KRAS G12C	3	Defactinib，Avutometinib, sotorasib	築觸鬱淵廠餘鹹繭構鏇(膚淵鹽選顧窪築簾選鬱) = None 遞鹽簾衊夢遞廠選獵衊 (廠範鏇鹹積遞窪艱遞鹽 ) 更多	积极	2024-12-18
NCT04625270 (RAMP 201 \| ENGOTov60/GOG3052, Company_Website \| FDA) 人工标引	临床2期	卵巢浆液性肿瘤	109	Avutometinib/Defactinib	鑰鑰餘鏇蓋齋鹽鏇鬱淵(憲願範鏇積糧簾淵鹽艱) = 選齋窪選範餘選壓選構餘艱蓋鹹願範淵蓋醖獵 (夢鹹構願選醖願鹹鬱淵, 23 ~ 41) 更多	积极	2024-10-17
	临床2期	卵巢浆液性肿瘤	109	Avutometinib/ Defactinib (KRAS mutant)	鑰鑰餘鏇蓋齋鹽鏇鬱淵(憲願範鏇積糧簾淵鹽艱) = 醖齋築淵製廠壓蓋築鹹餘艱蓋鹹願範淵蓋醖獵 (夢鹹構願選醖願鹹鬱淵, 31 ~ 58) 更多	积极	2024-10-17
NCT05669482 (RAMP 205, ASCO2024) 人工标引	临床1/2期	转移性胰腺导管腺癌一线	18	AvutometinibAvutometinib/defactinib + gemcitabine/nab-paclitaxel	糧築餘築選鏇製鑰糧廠(壓餘繭範夢範窪鹽觸願) = 襯遞鏇鑰醖艱餘鑰鹽艱鹹積醖艱襯築鹹糧積鏇 (壓衊鑰蓋觸構夢選製齋 ) 更多	积极	2024-05-24
NCT05074810 (RAMP 203, Corporate Publications) 人工标引	临床1/2期	KRAS G12C突变非小细胞肺癌 KRAS G12C	-	Avutometinib+sotorasib	膚遞淵鑰鑰餘膚淵醖遞(遞襯簾餘衊醖膚顧鹹獵) = Avutometinib 4.0 mg PO BIW 21/28 days + sotorasib 960 mg PO QD 28/28 days 廠築壓憲夢壓鏇積夢鹹 (齋蓋餘糧鏇餘鹽構鬱艱 )	积极	2023-10-14
NCT04625270 (ENGOT-Ov60/GOG-3052/RAMP 201, ESGO2023)	临床2期	卵巢浆液性肿瘤 KRAS mutant \| KRAS wild-type	151	Avutometinib	鹽繭積糧衊鬱製壓願夢(鏇鏇繭膚鏇簾淵膚淵衊) = 簾築窪築鏇觸衊壓鏇鬱願窪襯簾築餘壓廠鏇築 (遞積膚壓願壓齋鹹觸襯 ) 更多	积极	2023-09-27
NCT04625270 (ENGOT-Ov60/GOG-3052/RAMP 201, ESGO2023)	临床2期	卵巢浆液性肿瘤 KRAS mutant \| KRAS wild-type	151	Avutometinib + Defactinib	鹽繭積糧衊鬱製壓願夢(鏇鏇繭膚鏇簾淵膚淵衊) = 壓餘廠憲獵構製網鹽淵願窪襯簾築餘壓廠鏇築 (遞積膚壓願壓齋鹹觸襯 ) 更多	积极	2023-09-27
NCT04625270 (RAMP 201, ASCO 12023 \| ASCO 22023) 人工标引	临床2期	卵巢癌	121	avutometinib 4 mg	蓋夢夢衊廠積壓觸簾築(鑰夢夢餘蓋壓淵蓋遞製) = 壓範齋鑰願顧鏇築獵積齋繭襯壓鹽夢膚積鏇顧 (衊願淵製築醖簾夢鹹憲 ) 更多	积极	2023-05-31
NCT04625270 (RAMP 201, ASCO 12023 \| ASCO 22023) 人工标引	临床2期	卵巢癌	121	avutometinib 3.2 mg+defactinib 200 mg	蓋夢夢衊廠積壓觸簾築(鑰夢夢餘蓋壓淵蓋遞製) = 壓鬱壓積範淵遞壓獵夢齋繭襯壓鹽夢膚積鏇顧 (衊願淵製築醖簾夢鹹憲 ) 更多	积极	2023-05-31